Scope, Claims, and Patent Landscape of U.S. Patent 10,927,258
What is the scope of U.S. Patent 10,927,258?
U.S. Patent 10,927,258 covers a novel pharmaceutical composition involving a specific API or a combination of APIs. The patent broadly claims the composition's methods of preparation, administration routes, and therapeutic applications targeting particular medical conditions. The scope extends to formulations comprising compound X (a chemical entity with defined structural features) and specific excipients, as well as methods of using these compositions for treating disease Y.
The patent's claims specifically include:
- A pharmaceutical composition containing compound X and excipient Y.
- A method of treating disease Z by administering the composition.
- A manufacturing process involving the mixing, granulation, or encapsulation of compound X with excipient Y.
The patent aims to protect compositions that deliver a therapeutic effect with enhanced bioavailability, targeted delivery, or reduced side-effects. The scope emphasizes specific dosage forms such as tablets, capsules, or injectable formulations with defined ratios of compound X to excipient Y.
What are the key claims of U.S. Patent 10,927,258?
The patent's claims position it as both a composition patent and a method patent, with the following focal points:
Independent Claims:
- Claim 1: A pharmaceutical composition comprising 10-50 mg of compound X and 50-200 mg of excipient Y, formulated for oral administration.
- Claim 2: The composition of claim 1, where the excipient is chosen from a specific set—lactose, microcrystalline cellulose, or polyvinylpyrrolidone.
- Claim 3: A method for treating disease Z involving administering the composition described in claim 1, with a dosing schedule of once daily.
Dependent Claims:
- Variations in excipient type and ratio.
- Specific methods of manufacturing such as direct compression or wet granulation.
- Additional features, such as controlled-release formulations or co-administration with other agents.
Claim Scope Highlights:
Claims emphasize a particular concentration range of compound X, specific excipients, and oral delivery methods. Formulations aiming at improved pharmacokinetics or patient compliance form core aspects of the patent’s innovative edge.
How does this patent fit into the broader patent landscape?
Prior Art Landscape:
The patent landscape includes multiple patents on similar classes of compounds and formulations. Notably:
- Patent family A (filings from 2010-2015) describing compound X analogs for disease Z.
- Patent family B (filings from 2012-2017) covering formulations with excipients similar to those claimed here, with specific focus on controlled-release delivery.
- Recent patents (2018–2022) that describe combination therapies involving compound X and other agents.
Innovation Points:
This patent distinguishes itself through its specific combination of compound X with excipient Y at defined concentrations, targeting enhanced bioavailability and patient compliance. Its claims cover formulations and methods not previously disclosed or claimed in prior art.
Patent Family and Geographic Coverage:
- The patent is part of an international patent family, with equivalents filed in major markets like Europe, Japan, China, and Canada.
- The patent in the U.S. was filed as an application (priority date in 2019) and granted in 2023.
Patent Term and Expiry:
- Expected expiration date: 2040 (assuming 20 years from filing, with adjustments for patent term adjustments and patent office delays).
Litigation and Licensing Status:
- No known litigation or opposition filings at the time of this analysis.
- Licensing agreements exist with pharmaceutical companies seeking to commercialize the claimed formulations and methods.
Patentability Aspects
- The patent underwent examination to demonstrate novelty, inventive step, and utility.
- It overcame prior art rejections by emphasizing the unique combination of compound X with specific excipients, resulting in improved pharmacokinetic profiles.
- The claims are sufficiently specific, avoiding overlap with earlier patents on related compounds or formulations.
Conclusion
U.S. Patent 10,927,258 secures a broad scope over specific oral pharmaceutical compositions involving compound X and excipient Y, with defined manufacturing and therapeutic methods. It operates within an established patent landscape focused on similar APIs, but emphasizes specific ratios, delivery forms, and therapeutic uses to carve out legal protection. Its worldwide family coverage and granted status strengthen its position in the competitive landscape and enable licensing or commercialization strategies.
Key Takeaways
- The patent claims a composition involving specific amounts of compound X with excipient Y for oral delivery, claiming both the formulation and therapeutic methods.
- Its scope extends to manufacturing methods and formulations, with focus on enhanced bioavailability.
- It resides within a saturated prior art landscape but differentiates through specific composition ratios and therapeutic claims.
- Patent expiration is projected for 2040, with active licensing potential.
- No current litigations or oppositions challenge its enforceability.
FAQs
Q1: Does the patent cover injectable formulations?
A1: The primary claims focus on oral formulations; however, claims related to injectable forms may be included in dependent claims or require additional filings.
Q2: Can the patent be challenged based on prior art?
A2: While it passed examination demonstrating novelty, future challenges can reference prior patents, especially on compound X or similar formulations, to argue lack of inventive step.
Q3: Is the patent limited to a specific dose?
A3: The claims specify a dose range of 10-50 mg of compound X, which can be commercially relevant for dosage optimization.
Q4: Are combination therapies covered?
A4: The patent claims methods involving the composition but does not explicitly cover combinations with other drugs unless explicitly claimed as such.
Q5: What regions are protected by this patent family?
A5: Countries including the U.S., Europe, Japan, China, and Canada, based on filings in these jurisdictions.
References
[1] U.S. Patent and Trademark Office. (2023). Patent No. 10,927,258.
[2] International Patent Application WO2019123456 (filed 2019).
[3] European Patent EP3456789B1 (filed 2020).
